Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 5/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 0.72 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.65 |
| ▸ | KDM1A | O60341 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21063715 | 1.00 | PRCP (1.00) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL30973226 | 1.00 | PRCP (1.00) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL22728957 | 0.89 | PRCP (0.78) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL29478499 | 0.85 | PRCP (1.00) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL325083 | 0.85 | PRCP (1.00) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL1668148 | 0.85 | PRCP (1.00) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL327233 | 0.85 | PRCP (1.00) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL12046710 | 0.85 | PRCP (1.00) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL30721685 | 0.85 | PRCP (1.00) | PRCPGAARECQLGID4KDM1A | |
| Hydrochloric Acid SCHEMBL1735508 | 0.84 | GAA (1.00) | PRCPGAARECQLGID4KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118146154-A | Method for synergistic catalysis of selective oxidative dehydrogenation of tetrahydroisoquinoline | 西安石油大学 | 2024-06-07 | — | — | CN | disclosed |
| CN-108239029-B | Preparation and medical application of tetrahydroisoquinoline compounds and salts thereof | 中国医学科学院药物研究所 | 2021-04-13 | — | — | CN | disclosed |
| US-8476297-B2 | TRP-M8 receptor ligands and their use in treatments | AMGEN INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476297-B2 | TRP-M8 receptor ligands and their use in treatments | AMGEN INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476297-B2 | TRP-M8 receptor ligands and their use in treatments | AMGEN INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20100261728-A1 | TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261728-A1 | TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261728-A1 | TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2009073203-A1 | TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009073203-A1 | TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| EP-0801067-B1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | YAMANOUCHI PHARMA CO LTD (JP) | 2003-03-05 | — | — | EP | disclosed |
| US-6174896-B1 | MUSCARINIC RECEPTOR ANTAGONISTIC ACTIVITY; FOR THERAPY AND PROPHYLAXIS FOR UROLOGIC DISEASES, RESPIRATORY DISEASES OR DIGESTIVE DISEASES | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2001-01-16 | — | — | US | disclosed |
| US-6017927-A | Quinuclidine derivatives and medicinal composition thereof | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2000-01-25 | — | — | US | disclosed |
| EP-0801067-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1997-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261728-A1 | TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPM8, TRPV2 | PRCP 4619/4885GAA 1559/4885RECQL 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.